30 September 2016 – InDex Pharmaceuticals Holding AB (publ) (the “Company” or “InDex”) today announces the outcome of its initial public offering of new shares (the “Offering”) carried out in order to broaden the shareholder base and raise capital in connection with the planned listing on Nasdaq First North Stockholm.
The Offering period was between 14 and 27 September 2016. The Offering comprised a maximum of 29,761,905 new shares at a subscription price of SEK 8.40 per share, resulting in issue proceeds of a maximum of SEK 250 million before transaction costs. Subscription commitments and guarantee commitments had been provided equivalent to the entire issue and the results show that an equivalent of SEK 95.3 million was subscribed for by the general public and institutional investors, SEK 111 million was subscribed for in accordance with subscription commitments and the remaining SEK 43.7 million was subscribed for in accordance with guarantee commitments.
Subscribers of shares will receive contract notes with expected settlement date on 5 October 2016.
The board of directors has applied for listing of the Company’s shares at Nasdaq First North Stockholm. New shares under the Offering will only be registered provided that the application is approved. The first day of trading is planned to occur on or about 11 October 2016 and the shares will be traded under the short name “INDEX”.
In connection with the Offering and the listing, Stockholm Asset Management AB may, in its role as stabilising agent, on behalf of Stockholm Corporate Finance AB, participate in transactions that stabilise, maintain or otherwise affect the price of the shares in order to keep the market price of the shares at levels above those which might otherwise prevail in the open market.
As a result of the Offering, approximately 5,000 investors have been allotted shares in the Company. After registration of the Offering, the Company’s main owners (SEB Venture Capital, Stiftelsen Industrifonden, and NeoMed Management (together with N5 Investments)) will hold an equivalent of approximately 23, 21 and 11 percent, respectively, of the total number of shares in the Company. No new shareholder has been allotted shares equivalent to five (5) percent or more of the total number of shares in the Company after the completion of the Offering.
– We welcome all new shareholders and look forward to bring our lead drug candidate cobitolimod through the next value increasing phase using the capital raised. We will now initiate a phase IIb study in the debilitating inflammatory bowel disease ulcerative colitis with the goal to optimise the treatment with cobitolimod, says Peter Zerhouni, CEO of InDex Pharmaceuticals Holding.
Share structure and share capital
After registration of the new shares with the Swedish Companies Registration Office, there will only be one class of shares in the Company and the number of shares will increase by 29,761,905 as a result of the Offering and by an additional 2,634,279 as a result of an issue of new shares directed to a current shareholder (NeoMed Management/N5 Investments) in order to enable the settlement of different classes of shares. After registration, there will be a share capital of SEK 1,249,286.36 divided into a total of 62,463,418 shares in the Company.
InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The Company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis – a debilitating, chronic inflammation of the large intestine.
Cobitolimod is a new type of drug that can help patients with moderate to severe ulcerative colitis back to a normal life. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.
InDex is based in Stockholm with address Tomtebodavägen 23a, 171 77 Stockholm, Sweden. The Company’s operations are mainly conducted through its subsidiary Index Pharmaceuticals AB. For more information, please visit www.indexpharma.com.
About cobitolimod
Cobitolimod has a new type of mechanism of action. It is a so-called Toll-like receptor 9 (TLR9) agonist, that can provide an anti‐inflammatory effect locally in the large intestine, which may induce mucosal healing and relief of the clinical symptoms in ulcerative colitis.
Cobitolimod has achieved clinical proof-of-concept in moderate to severe active ulcerative colitis, with a very favorable safety profile. Data from four placebo-controlled clinical trials indicate that cobitolimod has statistically significant effects on those endpoints that are most relevant in this disease, both from a regulatory and clinical perspective. These endpoints include the key clinical symptoms such as blood in stool, number of stools, and mucosal healing, respectively.
In January 2016, WHO recommended the INN name cobitolimod. The substance is also known as Kappaproct® and DIMS0150.
Advisers and Certified Adviser
Stockholm Corporate Finance AB is the financial adviser and Setterwalls Advokatbyrå AB is the legal adviser to the Company in relation to the Offering and the listing. Aqurat Fondkommission AB acts as issuer agent in relation to the Offering. The Company has engaged Redeye AB as Certified Adviser.
For more information:
Peter Zerhouni, CEO
Phone no: +46 8 508 847 35
E-mail: [email protected]
Publication
This information is information that the Company is obliged to make public pursuant to the EU Market Abuse Regulation and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication through the agency of the contact person set out above at 08.30 CET on 30 September 2016.
IMPORTANT INFORMATION
This document has not been approved by any regulatory authority. The document is a press release and not a prospectus and investors should not subscribe for or purchase securities referred to in this document except on the basis of information contained in the prospectus that has been approved by the Swedish Financial Supervisory Authority and is kept available at the Company’s website. Distribution of this press release could in some jurisdictions be subject to restrictions according to law and recipients of this, or part of this, are required to inform themselves of, and comply with, such legal restrictions. Information in this press release should not constitute an offer to sell shares, or a solicitation of any offer to purchase shares, nor should any sale of the securities referred to herein be made, in any jurisdiction where such offer, solicitation of any offer to purchase, or sale would require preparing additional prospectus or other offering documents, or would not be lawful without registration or applicable exemptions from registering according to security acts in any such jurisdiction.
This press release neither constitutes, nor constitutes a part of, an offer or a solicitation of an offer to purchase or subscribe for securities in the United States. Securities referred to herein have not been, and will not be, registered in accordance with the American Securities Act of 1933 (“Securities Act”), and may not be offered or sold within the United States absent registration in accordance with the Securities Act, or an exemption therefrom. Securities referred to herein are not offered to the general public in the United States. Copies of this press release is not being made and may not be distributed or sent, in whole, or part, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or the United States or to any other jurisdiction where the distribution respectively the issuance of this press release would be unlawful.
